1. Effective antigen-specific immunotherapy in the marmoset model of multiple sclerosis.
- Author
-
McFarland HI, Lobito AA, Johnson MM, Palardy GR, Yee CS, Jordan EK, Frank JA, Tresser N, Genain CP, Mueller JP, Matis LA, and Lenardo MJ
- Subjects
- Animals, Autoantibodies biosynthesis, Brain pathology, Cytokines biosynthesis, Disease Models, Animal, Dose-Response Relationship, Immunologic, Drug Administration Schedule, Immunodominant Epitopes administration & dosage, Immunosuppressive Agents administration & dosage, Immunosuppressive Agents immunology, Injections, Intravenous, Lymphocyte Activation immunology, Magnetic Resonance Imaging, Male, Multiple Sclerosis pathology, Myelin Basic Protein administration & dosage, Myelin Proteolipid Protein administration & dosage, Recombinant Fusion Proteins administration & dosage, Recombinant Fusion Proteins immunology, Th1 Cells immunology, Th1 Cells metabolism, Th2 Cells immunology, Th2 Cells metabolism, Callithrix immunology, Immunodominant Epitopes immunology, Immunotherapy, Active methods, Multiple Sclerosis immunology, Multiple Sclerosis therapy, Myelin Basic Protein immunology, Myelin Proteolipid Protein immunology
- Abstract
Mature T cells initially respond to Ag by activation and expansion, but high and repeated doses of Ag cause programmed cell death and can suppress T cell-mediated diseases in rodents. We evaluated repeated systemic Ag administration in a marmoset model of experimental allergic encephalomyelitis that closely resembles the human disease multiple sclerosis. We found that treatment with MP4, a chimeric, recombinant polypeptide containing human myelin basic protein and human proteolipid protein epitopes, prevented clinical symptoms and did not exacerbate disease. CNS lesions were also reduced as assessed in vivo by magnetic resonance imaging. Thus, specific Ag-directed therapy can be effective and nontoxic in primates.
- Published
- 2001
- Full Text
- View/download PDF